Anser VDZ

Last Modified: 1/4/2021 6:39:12 AM

Medical Necessity Documentation:  
Client Notes:  
Patient Preparation:  
Specimen Requirements:  2.0 mL Serum in a SST Gold Top Tube
Collection Instructions:  
Transport & Storage: Temperature/Stability: 7 days Ambient
9 days Refrigerated
Reference Range: Serum vedolizumab concentration (VDZ) <1.6 ug/ml 
Antibodies to vedolizumab (ATV) concentration <1.6 U/ml
Critical Ranges:  
Test Comments:  
Methodology: Unlisted
Clinical Significance: Serum concentrations of vedolizumab (VDZ) may vary among equally dosed patients which can ultimately affect patient outcomes. Some patients may develop immunogenicity to VDZ by producing antibodies to vedolizumab (ATV) and the presence of persistent anti-vedolizumab antibody has been observed to substantially reduce serum concentrations of vedolizumab. The quantitative measurement of VDZ and ATV levels in serum provides healthcare providers with valuable information to help them gain a better understanding of the factors that may be affecting a patient’s loss of response.
The PROMETHEUS Anser VDZ test is a next generation and more sensitive quantitative monitoring assay that allows healthcare providers to measure and monitor serum VDZ and ATV levels at any time during therapy. Incorporating therapeutic drug monitoring may clarify what factors are contributing to a patient’s loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action.

A quantitative monitoring analysis of VDZ and ATV levels
Documentation:  Quantitative assay that simultaneously measures serum vedolizumab (VDZ) and antibodies to vedolizumab (ATV) concentrations
Custom Panel: No


Turn Around Time: 3 to 4 days
Sites Performed: Prometheus
PHL Test Code: NCSOT
EPIC Test Code:
Send Out Test Code: 3180
Alternate Test Names: VDZ; vedolizumab
Included Tests:  
CPT Coding: 80280, 82542

Go back to the top of the page.